



GOOD PEOPLE  
for GOOD HEALTH

August 4, 2022

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G-Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051.

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub: Outcome of meeting of Board of Directors – Unaudited Financial Results for the quarter ended June 30, 2022**

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find:

1. Unaudited standalone financial results for the quarter ended on June 30, 2022 accompanied by limited review report.
2. Unaudited consolidated financial results for the quarter ended on June 30, 2022 accompanied by limited review report.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 3.35 p.m. and concluded at 6.35 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

**For J.B. Chemicals & Pharmaceuticals Ltd.**

**Sandeep Phadnis**  
**Vice President - Secretarial**  
**& Company Secretary**

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Energy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

[www.jbpharma.com](http://www.jbpharma.com)

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Company"), for the quarter ended June 30, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No.36920)  
UDIN:22036920A0FRWN8542

 Place: MUMBAI  
Date: August 04, 2022







GOOD PEOPLE  
for GOOD HEALTH

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30/06/2022	31/03/2022	30/06/2021	31/03/2022
	Unaudited	Unaudited (Refer Note 6)	Unaudited	Audited
1. Revenue from operations	71,613	58,358	54,630	2,18,988
2. Other income	51	185	1,288	3,861
3. Total income (1+2)	71,664	58,543	55,918	2,22,849
4. Expenses				
a) Cost of materials consumed	18,586	16,035	14,788	60,187
b) Purchases of stock-in-trade	7,520	4,385	4,945	16,740
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(805)	(554)	(1,210)	(2,557)
d) Employee benefits expense (Refer note 3)	12,353	10,644	8,875	39,906
e) Finance costs	579	158	89	495
f) Depreciation and amortisation expense	2,569	2,179	1,748	7,128
g) Other expenses	17,161	15,688	11,401	53,821
Total expenses	57,963	48,535	40,636	1,75,720
5. Profit before tax (3-4)	13,701	10,008	15,282	47,129
6. Tax expense				
a) Current tax	2,400	3,100	3,800	12,250
b) Deferred tax	1,172	(1,364)	(49)	(1,221)
Total tax expense	3,572	1,736	3,751	11,029
7. Net profit after tax (5-6)	10,129	8,272	11,531	36,100
8. Other comprehensive income				
a) (i) Items that will not be reclassified to profit or loss	30	643	(212)	9
(ii) Income tax on items that will not be reclassified to profit or loss	(8)	(162)	53	(2)
b) (i) Items that will be reclassified to profit or loss	(346)	0	-	133
(ii) Income tax on items that will be reclassified to profit or loss	87	0	-	(33)
Total other comprehensive income (net of tax)	(237)	481	(159)	107
9. Total comprehensive income (7+8)	9,892	8,753	11,372	36,207
10. Paid-up equity share capital (face value ₹ 2/- each)	1,546	1,546	1,546	1,546
11. Other equity				2,08,821
12. Earnings per share (face value ₹ 2/- each)				
a) Basic (₹)	*13.11	*10.71	*14.92	46.71
b) Diluted (₹)	*13.08	*10.69	*14.92	46.67
*Not Annualised				

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai - 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Energy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai - 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE  
for GOOD HEALTH

**Notes:**

1. The above Standalone Financial Results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meetings held on August 04, 2022. The statutory auditors have carried out a limited review of the financial results of the Company for the quarter ended June 30, 2022. The results of the Company are available for investors at [www.jbpharma.com](http://www.jbpharma.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
3. The employee benefits expense for stock options during the quarter ended on June 30, 2022, March 31, 2022, June 30, 2021 and for the year ended March 31, 2022, includes charge of ₹1,634 lakhs, ₹ 2,361 lakhs, ₹ Nil and ₹ 6,092 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.  
The Company has granted 99,962 stock options on August 04, 2022, under "JBCPL Employee Stock Option Scheme, 2021".
4. On June 29, 2022, the Board of Directors of the Company approved the acquisition of portfolio of brands, for use and exploitation within India, from Dr Reddy's Laboratories Limited, for a consideration of ₹ 9,827 lakhs.
5. The Company has only one reportable business segment viz. "Pharmaceuticals".
6. The figures for the quarter ended March 31, 2022 are the balancing figures between the audited figures with respect to the full financial year upto March 31, 2022 and the unaudited published figures upto December 31, 2021 being the date of the end of the third quarter of the financial year which were subjected to limited review.
7. The Company considered the uncertainties relating to the geopolitical situation in Russia and Ukraine, in assessing the recoverability of receivables, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgements, estimates and assumptions, including sensitivity analysis, the Company expects to fully recover the carrying amount of receivables, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.
8. Results for the quarter ended June 30, 2022 include the impact of brands acquired during the previous quarter and current quarter.
9. Figures "0" represents amount less than ₹ 50,000, as the figures have been rounded off to the nearest lakh.

By order of the Board

For J.B. Chemicals & Pharmaceuticals Limited

Nikhil Chopra

Chief Executive Officer & Whole-time Director

Mumbai

August 04, 2022

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Energy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

[www.jbpharma.com](http://www.jbpharma.com)



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF J. B. CHEMICALS & PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2022 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:  
Parent - J. B. Chemicals & Pharmaceuticals Limited  
  
Direct Subsidiaries - OOO Unique Pharmaceutical Laboratories; and  
Unique Pharmaceutical Laboratories FZE.  
  
Step down Subsidiary - Biotech Laboratories (Pty.) Ltd.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 8,472.14 Lakhs for the quarter ended June 30, 2022, total net profit after tax of Rs. 535.02 Lakhs for the quarter ended June 30, 2022 and total comprehensive income of Rs. 535.02 Lakhs for the quarter ended June 30, 2022, as considered in the Statement. This interim financial information has been reviewed by another auditor whose report has been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenues of Rs. 1,512.84 Lakhs for the quarter ended June 30, 2022, total net profit after tax of Rs. 97.90 Lakhs for the quarter ended June 30, 2022 and total comprehensive income of Rs. 97.90 Lakhs for the quarter ended June 30, 2022, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
Partner  
(Membership No.36920)  
UDIN: 22036920A0F5JA7020

Place: MUMBAI  
Date: August 04, 2022







GOOD PEOPLE  
for GOOD HEALTH

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30/06/2022	31/03/2022	30/06/2021	31/03/2022
	Unaudited	Unaudited (Refer Note 6)	Unaudited	Audited
1. Revenue from operations	78,481	62,459	60,599	2,42,424
2. Other income	89	208	1,297	3,923
3. Total income (1+2)	78,570	62,667	61,896	2,46,347
4. Expenses				
a) Cost of materials consumed	18,588	16,047	14,793	60,222
b) Purchases of stock-in-trade	11,501	6,093	7,805	25,817
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(811)	(857)	(944)	(1,745)
d) Employee benefits expense (Refer note 3)	13,387	11,623	9,814	43,924
e) Finance costs	583	161	94	512
f) Depreciation and amortisation expense	2,608	2,211	1,785	7,266
g) Other expenses	18,540	17,061	12,762	59,861
Total expenses	64,396	52,339	46,109	1,95,857
5. Profit before tax (3-4)	14,174	10,328	15,787	50,490
6. Tax expense				
a) Current tax	2,591	3,209	3,943	12,815
b) Deferred tax	1,063	(1,378)	(62)	(929)
c) Reversal of excess current tax relating to earlier years	-	-	(0)	(0)
Total tax expense	3,654	1,831	3,881	11,886
7. Net profit after tax (5-6)	10,520	8,497	11,906	38,604
8. Other comprehensive income				
a) (i) Items that will not be reclassified to profit or loss	30	644	(212)	9
(ii) Income tax on items that will not be reclassified to profit or loss	(8)	(162)	53	(2)
b) (i) Items that will be reclassified to profit or loss	(59)	989	493	427
(ii) Income tax on items that will be reclassified to profit or loss	87	0	-	(33)
Total other comprehensive income (net of tax)	50	1,471	334	401
9. Total comprehensive income after tax (7+8)	10,570	9,968	12,240	39,005
10. Net profit after tax for the period/year attributable to :				
a) Owners of the company	10,503	8,484	11,887	38,536
b) Non-controlling interest	17	13	19	68
11. Other comprehensive income for the period attributable to :				
a) Owners of the company	87	1,428	319	390
b) Non-controlling interest	(37)	43	15	11
12. Total comprehensive income after tax attributable to :				
a) Owners of the company	10,590	9,912	12,206	38,926
b) Non-controlling interest	(20)	56	34	79
13. Paid-up equity share capital (face value ₹ 2/- each)	1,546	1,546	1,546	1,546
14. Other equity				2,11,867
15. Earnings per share (face value ₹ 2/- each)				
a) Basic (₹)	*13.59	*10.98	*15.38	49.86
b) Diluted (₹)	*13.56	*10.96	*15.38	49.82
*Not Annualised				

Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai - 400030, T:+91 22 24822222

Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai - 400025, T:+91 22 24395200/5500

www.jbpharma.com



GOOD PEOPLE  
for GOOD HEALTH

**Notes:**

1. The above consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on August 04, 2022. The statutory auditors have carried out a limited review of the financial results of the Company for the quarter ended June 30, 2022. The results of the Company are available for investors at [www.jbpharma.com](http://www.jbpharma.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder, and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The Consolidated Financial Results of the Holding Company, its wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
3. The employee benefits expense for stock options during the quarter ended on June 30, 2022, March 31, 2022, June 30, 2021 and for the year ended March 31, 2022, includes a charge of ₹ 1,698 lakhs, ₹ 2,437 lakhs, ₹ Nil and ₹ 6,265 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.  
The Company has granted 99,962 stock options on August 04, 2022, under "JBCPL Employee Stock Option Scheme, 2021".
4. On June 29, 2022, the Board of Directors of the Holding Company approved the acquisition of portfolio of brands, for use and exploitation within India, from Dr. Reddy's Laboratories Limited, for a consideration of ₹ 9,827 lakhs.
5. The Group has only one reportable business segment viz., "Pharmaceuticals".
6. The figures for the quarter ended March 31, 2022 are the balancing figures between the audited figures with respect to the full financial year upto March 31, 2022 and the unaudited published figures upto December 31, 2021 being the date of the end of the third quarter of the financial year which were subjected to limited review.
7. The Group considered the uncertainties relating to the geopolitical situation in Russia and Ukraine, in assessing the recoverability of receivables, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. Based on its judgements, estimates and assumptions, including sensitivity analysis, the Company expects to fully recover the carrying amount of receivables, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.
8. Results for the quarter ended June 30, 2022 include the impact of brands acquired during the previous quarter and current quarter.
9. Figures "0" represents amount less than ₹ 50,000, as the figures have been rounded off to the nearest lakh.

By order of the Board  
For J.B. Chemicals & Pharmaceuticals Limited

**Nikhil Chopra**

Chief Executive Officer & Whole-time Director

Mumbai  
August 04, 2022

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Energy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

[www.jbpharma.com](http://www.jbpharma.com)